CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 217 enrolled
Drug / intervention
Rabeprazole +1 moredrug
Likely dose
Rabeprazole 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01008696
NCT01008696Phase 4Completed
CompareCT.gov

Effect of Rabeprazole and Lansoprazole on Reflux Esophagitis in Relation to CYP2C19 Genotype Status: A Prospective, Randomized, Multicenter Study

Janssen Korea, Ltd., Korea·interventional·Posted Nov 6, 2009·Updated Aug 13, 2013

In Brief

A Phase 4 clinical trial evaluating Rabeprazole and Lansoprazole for Reflux Esophagitis. Completed, enrolled 217 participants.

Detailed Summary

The purpose of this study is to compare the treatment effects of rabeprazole and lansoprazole depending on the genotyping (process of determining the genetic constitution) of CYP2C19 in treating reflux esophagitis (caused by gastroesophageal reflux; deterioration of the protective lining on the inner wall of the lower esophagus); and to evaluate the cure rate of reflux esophagitis on endoscopy (a thin flexible tube with a microscopic camera at the end which is passed down your throat into the esophagus, stomach, and duodenum) after treatment with rabeprazole and lansoprazole.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsReflux Esophagitis
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 6, 2009
Enrollment StartMay 1, 2007
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.7 years ago

Interventions

Rabeprazoledrug

Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.

Lansoprazoledrug

Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.